New Radiopharmaceutical [18F] Fluormisonidazole

A firm called Company RadioMedic Ltd., developed at the Nuclear Physics Institute of the ASCR in 2009, deals with the development, manufacturing and distribu­tion of radiopharmaceutical preparations. It has developed a radio­pharmaceutical with an active substance that selecti­vely binds to hypoxic cells. These tumor cells are more sensitive to radiotherapy and chemotherapy in the presence of oxygen in tissue and consequently the number of the hypoxic cells is a limiting factor for a therapy effect.